Medicus Pharma Ltd.
NCM: MDCXLive Quote
About Medicus Pharma Ltd.
Healthcare
Drug Manufacturers - General
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in Conshohocken, Pennsylvania.
📊 Fundamental Analysis
Medicus Pharma Ltd. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -2981.2%, which indicates that capital utilization is currently under pressure.
At a current price of $0.41, MDCX currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $0.37 - $8.94).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$18.28M
Trailing P/E
--
Forward P/E
-1.02
Beta (5Y)
-0.04
52W High
$8.94
52W Low
$0.37
Avg Volume
4.03M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App